The Guardian Australia

Why UK has been less keen than US to give Covid jab to children

- Nicola Davis and Jessica Glenza

The UK and US may have many things in common, but when it comes to vaccinatin­g children against Covid, the approach has been markedly different.

In May, the US Food and Drug Administra­tion’s emergency use authorisat­ion of the Pfizer/BioNTech jab was expanded from people aged 16 and older to those aged 12 to 15, with two doses recommende­d for all those eligible.

In late October, the FDA went further, extending it to five- to 11-yearolds – although with lower doses than older age groups. Since then some experts, including the American Academy of Pediatrics, have pushed strongly for even younger children to be vaccinated.

However, the UK has shown significan­tly less speed in expanding its Covid vaccinatio­n programmes to children despite a successful rollout among adults, with almost 70% of the population having had two jabs.

The Medicines and Healthcare products Regulatory Agency (MHRA) approved the Pfizer/BioNTech vaccine in June for children aged 12-15 and the Moderna jab for 12- to 17-year-olds in August. However, a first dose was only made available to 12- to 15-yearolds from 13 September. The decision was finally made by the UK’s four chief medical officers after the Joint Committee on Vaccinatio­n and Immunisati­on (JCVI) advised that while the health gains from vaccinatin­g this group were greater than the risks, “the margin of benefit is considered too small” to support it on health grounds alone.

The Guardian understand­s the JCVI is already discussing whether the vaccinatio­n programme should be expanded to children as young as five.

Meanwhile leaked reports suggest the NHS is already preparing to roll out the jab to this age group in the spring.

However, the MHRA has yet to announce whether, like the FDA and European Medicines Agency, it will approve the use of Covid jabs for younger children.

Covid infection levels have remained high for months in the UK, with

school-age children among the most affected. The daily case numbers are expected to hit new records as a result of the Omicron variant, which has been found to dodge – at least to some degree – the immune responses provided by vaccinatio­n or natural infection.

In the US, many experts believe the case for vaccinatio­n of children is clear cut.

“The Delta wave in the summer convinced everybody that Covid-19 can cause a lot of devastatin­g illness in kids and adolescent­s,” said Dr Peter Hotez, co-director of Texas children’s hospital Center for Vaccine Developmen­t.

Hotez, who is also dean of National School of Tropical Medicine at Baylor College of Medicine, said the UK’s decision was perhaps based on “local data” that differed from the US experience.

Other US experts advocate vaccines for young children as a tool to prevent this age group from becoming a reservoir of disease, which could pass Covid-19 to high risk groups such as grandparen­ts.

However, the JCVI has cited concerns over a very rare side-effect linked to Covid jabs among young people, myocarditi­s, including the potential long-term effects of the condition. Among other issues, the JCVI has also been concerned about the impact of rolling out Covid jabs to older children could have on the delivery of other school immunisati­on programmes.

With children far less likely than adults to become seriously ill with Covid, there was an ethical concern over the appropriat­eness of vaccinatin­g children to protect others. This was particular­ly acute given the uncertaint­y about the impact the vaccinatio­n of 12to 15-year-olds would have on transmissi­on in the face of the Delta variant.

One expert, who is no longer part of the JCVI, suggested it could be better for children to gain protection from natural infection rather than taking a possible risk with a vaccine.

Some scientists described the reluctance of the JCVI to approve jabs for older children “completely shocking”, with further concerns raised after it emerged its decision was taken despite modelling that suggested a rollout would reduce infections, hospitalis­ations and some deaths in this age group.

However, Russell Viner, professor of adolescent health at University College London Institute of Child Health, and a participan­t in the Scientific Advisory Group for Emergencie­s during the pandemic, suggested there were a number of reasons why the UK and US have taken different approach, including cultural difference­s in medicine.

“US physicians are generally much more pro-interventi­onist. In the UK there is a stronger recognitio­n of the potential for harm,” he said.

Viner also noted the US has been hard hit by Covid in terms of children. “Their health system does not protect the vulnerable and deprived as ours does,” he said.

Although the UK had not handled the pandemic as well as some other countries with regard to adults, Viner added, “we have done very well in terms of children and serious Covid disease”.

One source with knowledge of JCVI matters said a key difference between the UK and the US was that in the latter, parents may have to pay for expensive care for their child if they fell ill. The US has also had lower uptake of jabs among adults, which could be driving the push to vaccinate children to try stem the pandemic, the source added.

But the question remains whether the UK and the US will eventually end up at the same destinatio­n, and to what degree Omicron has changed the equation.

 ?? Photograph: David Ryder/Getty Images ?? A nine-year-old boy prepares to receive the Pfizer/BioNtech Covid-19 vaccine in Washington state, US.
Photograph: David Ryder/Getty Images A nine-year-old boy prepares to receive the Pfizer/BioNtech Covid-19 vaccine in Washington state, US.

Newspapers in English

Newspapers from Australia